Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF UROLOGY
Volume 25, Issue 3, Pages 196-205
Publisher
Wiley
Online
2017-12-05
DOI
10.1111/iju.13498
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice
- (2017) Christopher R. Chapple et al. EUROPEAN UROLOGY
- Long-term Persistence with Mirabegron versus Solifenacin in Women with Overactive Bladder: Prospective, Randomized Trial
- (2016) Manami KINJO et al. LUTS-Lower Urinary Tract Symptoms
- American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults
- (2015) JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder
- (2014) Osamu Yamaguchi et al. BJU INTERNATIONAL
- Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia
- (2014) Hann-Chorng Kuo et al. NEUROUROLOGY AND URODYNAMICS
- The Role of Mirabegron in Overactive Bladder: A Systematic Review and Meta-Analysis
- (2014) Tao Wu et al. UROLOGIA INTERNATIONALIS
- Systematic Review of Combination Drug Therapy for Non-neurogenic Male Lower Urinary Tract Symptoms
- (2013) Claudius Füllhase et al. EUROPEAN UROLOGY
- Global Prevalence and Economic Burden of Urgency Urinary Incontinence: A Systematic Review
- (2013) Ian Milsom et al. EUROPEAN UROLOGY
- Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies
- (2013) V. W. Nitti et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- A phase II dose-ranging study of mirabegron in patients with overactive bladder
- (2013) Christopher R. Chapple et al. INTERNATIONAL UROGYNECOLOGY JOURNAL
- The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials
- (2013) Yuanshan Cui et al. INTERNATIONAL UROLOGY AND NEPHROLOGY
- Urodynamics and Safety of the β3-Adrenoceptor Agonist Mirabegron in Males with Lower Urinary Tract Symptoms and Bladder Outlet Obstruction
- (2013) Victor W. Nitti et al. JOURNAL OF UROLOGY
- Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability
- (2013) Christopher R. Chapple et al. NEUROUROLOGY AND URODYNAMICS
- A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder
- (2013) Sender Herschorn et al. UROLOGY
- Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience
- (2012) Adrian Wagg et al. BJU INTERNATIONAL
- Proarrhythmic Safety of Repeat Doses of Mirabegron in Healthy Subjects: A Randomized, Double-Blind, Placebo-, and Active-Controlled Thorough QT Study
- (2012) M Malik et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder
- (2012) Christopher R. Chapple et al. EUROPEAN UROLOGY
- Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial
- (2012) Vik Khullar et al. EUROPEAN UROLOGY
- Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive Bladder
- (2012) Victor W. Nitti et al. JOURNAL OF UROLOGY
- Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence
- (2009) Karl-Erik Andersson et al. CURRENT OPINION IN UROLOGY
- Reviewing the ICS 2002 terminology report: The ongoing debate
- (2009) Paul Abrams et al. NEUROUROLOGY AND URODYNAMICS
- Stimulation of β3-adrenoceptors relaxes rat urinary bladder smooth muscle via activation of the large-conductance Ca2+-activated K+ channels
- (2008) Kiril L. Hristov et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Potentiation of Potassium Currents by Beta-Adrenoceptor Agonists in Human Urinary Bladder Smooth Muscle Cells: A Possible Electrical Mechanism of Relaxation
- (2008) Jun Takemoto et al. PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started